Our novel solution, BrainSeeTM, is a Software as a Service (SaaS) platform. Doctors provide standard clinical brain MRI scans (T1, T2 FLAIR, and DWI/DTI), and BrainSee analyzes the scans in a few hours and provides detailed brain maps with exact quantification of neurodegeneration in each voxel, as well as a summary score that reflects the person’s brain health and the likelihood of future cognitive decline.
Darmiyan has developed a novel, proprietary, patent-protected technology called The Virtual Microscope (Software Algorithm). Using a non-invasive routine clinical brain MRI scan, The Virtual Microscope technology looks into the human brain and localizes and quantifies cell distortion (neurodegeneration) in every voxel of brain MRI generating new brain maps. The first clinical product of this technology is BrainSee, an AI-powered algorithm that has completed a successful third-party validation in the US and Canada establishing a remarkable accuracy and consistency for the prognosis of mild cognitive impairment. It is built on over 40 years of cutting-edge neuroscience research combined with advanced medical image analysis and AI and has received official approval
Total Funding: $11.1 M
Funding Stage: Seed
Business Stage: Scaling Up
Market: B2B
Company Size: 26 to 50
Founded: 2016
For AI Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI Startup founders or founders at Darmiyan
Senior Machine Learning and AI Expert
San Francisco, California
Medical Data Scientist
San Francisco, California
Senior Data Analytics and Visualization Engineer
San Francisco, California
Senior Brain Image Processing Expert
San Francisco, California
Director of Regulatory Affairs
San Francisco, California
Darmiyan - AI Startup | AI Startup Profile Powered by Appengine AI | Appengine AI - AI Ecosystem of 12,000+ AI Startups
Darmiyan - Manage Profile